spacer
home > epc > spring 2002 > drug information association's 14th annual euromeeting - basel, switzerland, 5th-8th march 2002
PUBLICATIONS
European Pharmaceutical Contractor

Drug Information Association's 14th Annual EuroMeeting - Basel, Switzerland, 5th-8th March 2002

The 14th annual DIA EuroMeeting is based on the premise that in the 21st Century only a relatively small proportion of all diseases can be adequately treated, nevermind cured. At a fundamental level there is a lack of understanding of the mechanism of disease - particularly the genetic basis of disease and its implications for rational drug treatment.

Of equal concern is that only a small proportion of all patients have access to safe medicinal products at affordable prices. The availability of safe and effective medicines is a real issue in third world countries where for many patients the cost of diagnosis and treatment are beyond their means. This leads to counterfeit and often dangerous substitutes being sold in those countries. Where treatments are available there is often a lack of clear information on the products and their rational use.

Regulatory authorities, government health departments and medical insurance companies add their own particular and specific hurdles to the early availability of effective treatments.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

 You must be a member of the site to make a comment.
spacer
By Richard Barrett of Pfizer Global Research and Development, UK

Richard Barrett of Pfizer Global Research and Development, UK is the Co-Chairperson of the Euro2002 Programme Committee, along with Manuel Zahn, of AstraZeneca, Sweden.
spacer
Richard Barrett
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Nemera acquires Insight Product Development to strengthen its capabilities

“Every day at Nemera, we work to improve the lives of millions of patients worldwide by designing, developing and manufacturing innovative drug delivery devices. Our vision as a team is to become the most patient-centric drug delivery device company in the industry. We partner closely with our customers to deliver innovative and high quality devices, to ensure that patients will receive the best product and service possible” Marc Hämel, CEO
More info >>

White Papers

Clinical Trials in Ukraine: Orange Paper Overview and 1st Half Year 2014

Synergy Research Group

The Orange Paper is an analytical report about the clinical trials market in Russia, published quarterly by the contract research organization Synergy Research Group. The first edition of Orange Paper was released in 2006, and at the moment 31 issues have already published. Now, thanks to Synergy Group Ukraine, obtaining information about the market of clinical trials in Ukraine has become possible. In Ukraine, during the period from 1996 to 2013, applicants had obtained 3,864 positive conclusions about the possibility of conducting clinical trials of drugs, both for domestic and foreign manufacturers, including conduct of multinational multi-center clinical trials (hereinafter – MMCTs)
More info >>

 
Industry Events

CPhI & P-MEC India

26-28 November 2019, India Expo Centre, Greater Noida, Delhi NCR, India

As the pharma industry looks increasingly towards India forhigh quality, low   cost pharma solutions, CPhI & P-MEC Indiais the ideal event for companies wanting to pick up on the latest trends and innovations the market has to offer. At CPhI & P-MEC India, you will meet the movers and shakers from India’s pharma machinery, technology and ingredients industries, giving you a competitive advantage that will help grow your business.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement